51 related articles for article (PubMed ID: 16740765)
1. Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors.
Mukohara T; Nagai S; Koshiji M; Yoshizawa K; Minami H
Cancer Sci; 2010 Oct; 101(10):2193-9. PubMed ID: 20707806
[TBL] [Abstract][Full Text] [Related]
2. Mass cytometry as a tool in target validation and drug discovery.
Watson ECR; Baker W; Ahern D; Loi D; Cribbs AP; Oppermann U
Methods Enzymol; 2023; 690():541-574. PubMed ID: 37858540
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory effects of α-MSH through p-CREB expression in sarcoidosis like granuloma model.
Zhang C; Chery S; Lazerson A; Altman NH; Jackson R; Holt G; Campos M; Schally AV; Mirsaeidi M
Sci Rep; 2020 Apr; 10(1):7277. PubMed ID: 32350353
[TBL] [Abstract][Full Text] [Related]
4. Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation.
Zwergel C; Fioravanti R; Stazi G; Sarno F; Battistelli C; Romanelli A; Nebbioso A; Mendes E; Paulo A; Strippoli R; Tripodi M; Pechalrieu D; Arimondo PB; De Luca T; Del Bufalo D; Trisciuoglio D; Altucci L; Valente S; Mai A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32075099
[TBL] [Abstract][Full Text] [Related]
5. Fas signaling-mediated T
Shen Y; Song Z; Lu X; Ma Z; Lu C; Zhang B; Chen Y; Duan M; Apetoh L; Li X; Guo J; Miao Y; Zhang G; Yang D; Cai Z; Wang J
Nat Commun; 2019 Jul; 10(1):2924. PubMed ID: 31266950
[TBL] [Abstract][Full Text] [Related]
6. FLT3, a prognostic biomarker for acute myeloid leukemia (AML): Quantitative monitoring with a simple anti-FLT3 interaction and flow cytometric method.
Ampasavate C; Jutapakdee W; Phongpradist R; Tima S; Tantiworawit A; Charoenkwan P; Chinwong D; Anuchapreeda S
J Clin Lab Anal; 2019 May; 33(4):e22859. PubMed ID: 30737839
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase C pharmacology: refining the toolbox.
Wu-Zhang AX; Newton AC
Biochem J; 2013 Jun; 452(2):195-209. PubMed ID: 23662807
[TBL] [Abstract][Full Text] [Related]
8. CD95 triggers Orai1-mediated localized Ca2+ entry, regulates recruitment of protein kinase C (PKC) β2, and prevents death-inducing signaling complex formation.
Khadra N; Bresson-Bepoldin L; Penna A; Chaigne-Delalande B; Ségui B; Levade T; Vacher AM; Reiffers J; Ducret T; Moreau JF; Cahalan MD; Vacher P; Legembre P
Proc Natl Acad Sci U S A; 2011 Nov; 108(47):19072-7. PubMed ID: 22065776
[TBL] [Abstract][Full Text] [Related]
9. Discovering Molecular Targets in Cancer with Multiscale Modeling.
Wang Z; Bordas V; Deisboeck TS
Drug Dev Res; 2011 Feb; 72(1):45-52. PubMed ID: 21572568
[TBL] [Abstract][Full Text] [Related]
10. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Usha L; Sill MW; Darcy KM; Benbrook DM; Hurteau JA; Michelin DP; Mannel RS; Hanjani P; De Geest K; Godwin AK
Gynecol Oncol; 2011 Jun; 121(3):455-61. PubMed ID: 21414654
[TBL] [Abstract][Full Text] [Related]
11. Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.
Willey CD; Xiao D; Tu T; Kim KW; Moretti L; Niermann KJ; Tawtawy MN; Quarles CC; Lu B
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1518-26. PubMed ID: 19906497
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.
Meng XW; Heldebrant MP; Flatten KS; Loegering DA; Dai H; Schneider PA; Gomez TS; Peterson KL; Trushin SA; Hess AD; Smith BD; Karp JE; Billadeau DD; Kaufmann SH
J Biol Chem; 2010 Jan; 285(2):888-902. PubMed ID: 19887445
[TBL] [Abstract][Full Text] [Related]
13. Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis.
Kim J; Choi YL; Vallentin A; Hunrichs BS; Hellerstein MK; Peehl DM; Mochly-Rosen D
Cancer Res; 2008 Aug; 68(16):6831-9. PubMed ID: 18701509
[TBL] [Abstract][Full Text] [Related]
14. Cross-scale sensitivity analysis of a non-small cell lung cancer model: linking molecular signaling properties to cellular behavior.
Wang Z; Birch CM; Deisboeck TS
Biosystems; 2008 Jun; 92(3):249-58. PubMed ID: 18448237
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometry for drug discovery, receptor pharmacology and high-throughput screening.
Sklar LA; Carter MB; Edwards BS
Curr Opin Pharmacol; 2007 Oct; 7(5):527-34. PubMed ID: 17652026
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Jimeno A; Rudek MA; Purcell T; Laheru DA; Messersmith WA; Dancey J; Carducci MA; Baker SD; Hidalgo M; Donehower RC
Cancer Chemother Pharmacol; 2008 Mar; 61(3):423-33. PubMed ID: 17429623
[TBL] [Abstract][Full Text] [Related]
17. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).
Podar K; Raab MS; Zhang J; McMillin D; Breitkreutz I; Tai YT; Lin BK; Munshi N; Hideshima T; Chauhan D; Anderson KC
Blood; 2007 Feb; 109(4):1669-77. PubMed ID: 17023575
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Green LJ; Marder P; Ray C; Cook CA; Jaken S; Musib LC; Herbst RS; Carducci M; Britten CD; Basche M; Eckhardt SG; Thornton D
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3408-15. PubMed ID: 16740765
[TBL] [Abstract][Full Text] [Related]
19. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
